

119TH CONGRESS  
2D SESSION

# H. R. 8630

To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

APRIL 30, 2026

Mr. RULLI (for himself and Mrs. HARSHBARGER) introduced the following bill;  
which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Protecting Equal Ac-  
5 cess to Thyroid Act of 2026” or the “PEAT Act of 2026”.

1 **SEC. 2. PROHIBITION WITH RESPECT TO TREATMENT OF**  
2 **PROTEINS IN BIOLOGICS.**

3 (a) IN GENERAL.—Section 351(i)(1) of the Public  
4 Health Service Act (42 U.S.C. 262(i)(1)) is amended—

5 (1) by striking “The term” and inserting the  
6 following:

7 “(A) The term”; and

8 (2) by adding at the end the following:

9 “(B) A biologic described in subparagraph

10 (A) may not be treated as a biological product  
11 based solely on the presence of a protein that  
12 is a clinically inactive component in such bio-  
13 logic.”.

14 (b) TECHNICAL CORRECTION.—Section 351(i)(1) of  
15 the Public Health Service Act (42 U.S.C. 262(i)(1)) is  
16 amended in subparagraph (A), as designated by sub-  
17 section (a)(1), by striking “protein ,” and inserting “pro-  
18 tein,”.

○